AA
ASND icon

AQR Arbitrage’s Ascendis Pharma A/S ASND Stock Holding History

AQR Arbitrage’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,058
Closed -$1.89M – 1505
2022
Q1 		$1.89M Buy
+16,058
New +$1.86M 0.05% 386

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AQR Arbitrage's ASND Position: Q2 2022 in Review

AQR Arbitrage sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 16,058 shares — an estimated $1.89M sold.

AQR Arbitrage first reported a position in ASND in Q1 2022 and held it in 1 quarter. The position peaked at $1.89M in Q1 2022. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

  • AQR Arbitrage reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
  • AQR Arbitrage sold 16,058 Ascendis Pharma A/S shares in Q2 2022, an estimated $1.89M.
  • AQR Arbitrage first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 1 quarter.
  • AQR Arbitrage's Ascendis Pharma A/S position peaked at $1.89M in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on AQR Arbitrage's 13F filing for Q2 2022, filed 15 Aug 2022.